{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000014","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.542356+00:00","generated_at":"2026-05-23T01:35:48.859455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront","bullets":["GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.","LEQEMBI global in-market sales ~$96M; SKYCLARYS global revenue ~$124M; launch products more than doubled YoY.","Updated FY2025 non-GAAP EPS guidance $14.50-$15.50; total revenue expected to decline mid-single-digit constant currency.","Felzartamab Phase 3 study initiated in antibody-mediated rejection; BIIB080 (tau ASO) received FDA Fast Track designation.","Zorevunersen collaboration with Stoke ($165M upfront) for Dravet syndrome; pivotal Phase 3 to start in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000014","json":"https://secwatch.observer/filing/0000875045-25-000014.json","markdown":"https://secwatch.observer/filing/0000875045-25-000014.md","text":"https://secwatch.observer/filing/0000875045-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/0000875045-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/biib-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:35:48.859455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}